Granahan Investment Management’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.1M Buy
461,608
+126,022
+38% +$4.04M 0.54% 50
2026
Q1
$10.9M Buy
335,586
+144,189
+75% +$4.73M 0.53% 51
2025
Q4
$6.07M Sell
191,397
-62,502
-25% -$1.88M 0.26% 92
2025
Q3
$5.97M Sell
253,899
-278,514
-52% -$4.77M 0.24% 85
2025
Q2
$6.04M Sell
532,413
-128,017
-19% -$1.22M 0.25% 92
2025
Q1
$4.39M Buy
660,430
+92,741
+16% +$865K 0.22% 101
2024
Q4
$6.26M Sell
567,689
-77,281
-12% -$949K 0.26% 92
2024
Q3
$7.93M Buy
644,970
+46,569
+8% +$660K 0.31% 96
2024
Q2
$8.08M Buy
598,401
+122,938
+26% +$1.66M 0.32% 89
2024
Q1
$6.42M Sell
475,463
-662,424
-58% -$4.01M 0.23% 115
2023
Q4
$5.99M Buy
1,137,887
+286,686
+34% +$1.23M 0.2% 122
2023
Q3
$3.35M Buy
851,201
+318,321
+60% +$2.09M 0.12% 143
2023
Q2
$5.66M Sell
532,880
-70,644
-12% -$752K 0.17% 127
2023
Q1
$5.03M Buy
603,524
+53,305
+10% +$481K 0.15% 125
2022
Q4
$5.08M Buy
550,219
+291,205
+112% +$3.03M 0.16% 129
2022
Q3
$3.33M Buy
259,014
+60,393
+30% +$962K 0.11% 146
2022
Q2
$2.62M Buy
+198,621
New +$3.02M 0.09% 152

Other funds holding STOK

Granahan Investment Management's STOK Position: Q2 2026 in Review

Granahan Investment Management increased its Stoke Therapeutics (STOK) stake by 38% in Q2 2026, buying an estimated $4.04M and bringing the position to 461,608 shares worth $15.1M. The position accounts for 0.54% of the portfolio, ranked #50.

Granahan Investment Management first reported a position in STOK in Q2 2022 and has held it in 17 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Granahan Investment Management held 461,608 shares of Stoke Therapeutics worth $15.1M as of Q2 2026.
  • Granahan Investment Management bought 126,022 Stoke Therapeutics shares in Q2 2026, an estimated $4.04M.
  • Stoke Therapeutics made up 0.54% of Granahan Investment Management's portfolio in Q2 2026, its #50 holding.
  • Granahan Investment Management first reported a position in Stoke Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.